Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacoeconomic evaluation of Anbainuo for moderate to severe rheumatoid arthritis
ChiCTR2000032534Phase 4Completed
- Sponsor
- Zhuzhou Central Hospital
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of anbainuo in rheumatoid arthritis (RA) (2 arms), sponsored by Zhuzhou Central Hospital. Primary endpoints: ACR20 response, DAS28 and 2 more. Started May 2019; status: completed.
02
Drugs
anbainuo
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2000032534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032534.